Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Kyverna a "Moderate Buy" — five covering firms average a "Moderate Buy" rating (four buys, one sell) with a 1‑year consensus target of about $28.67, versus the stock trading near $9.21.
• Financials/market snapshot: Kyverna reported quarterly EPS of ($0.80) in line with estimates, carries a negative P/E, a market cap of roughly $557.5M, and a 1‑year trading range of $1.92–$13.67.
• Company profile and investor activity: Kyverna is a clinical‑stage developer of engineered Treg cell therapies (lead allogeneic program for ulcerative colitis), and several hedge funds have recently built or increased positions (AIGH now owns 2.0M shares); institutional ownership is about 18.1%.

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $28.6667.

Several analysts recently weighed in on the company. Wall Street Zen downgraded Kyverna Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Kyverna Therapeutics in a research note on Thursday, April 23rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kyverna Therapeutics in a report on Friday, March 27th.

Kyverna Therapeutics Trading Up 2.3%

Shares of NASDAQ KYTX opened at $9.21 on Wednesday. Kyverna Therapeutics has a 1 year low of $1.92 and a 1 year high of $13.67. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The firm has a 50-day moving average of $8.76 and a 200 day moving average of $8.22. The stock has a market cap of $557.48 million, a P/E ratio of -2.52 and a beta of 2.05.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.80). As a group, sell-side analysts expect that Kyverna Therapeutics will post -3.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC increased its stake in Kyverna Therapeutics by 33.3% during the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company's stock valued at $17,260,000 after purchasing an additional 500,000 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in shares of Kyverna Therapeutics in the first quarter worth approximately $991,000. Wesbanco Bank Inc. purchased a new stake in shares of Kyverna Therapeutics during the first quarter valued at approximately $952,000. Grey Ledge Advisors LLC purchased a new stake in shares of Kyverna Therapeutics during the first quarter valued at approximately $86,000. Finally, Banque Cantonale Vaudoise bought a new stake in shares of Kyverna Therapeutics during the first quarter valued at approximately $263,000. Institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company's lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.